People taking popular GLP-1 obesity drugs who remain on low starter doses will ​lose some weight but

Telehealth company Hims & Hers said on Monday it has begun offering branded GLP-1 weight-loss drugs

Eli Lilly generated nearly two-thirds of its sales from GLP-1 drugs in the second quarter of 2026. A

Employer insurance coverage for GLP-1 weight-loss drugs is shrinking, yet Eli Lilly just posted a 47

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

Deutsche Bank downgrades Novo Nordisk, citing doubts over the drugmaker's ability to return to growt

LLY's oncology revenues rise 11% in the first half of 2026, as newer drugs gain traction and pipelin

Novo Nordisk (NYSE:NVO) has received a downgrade from Deutsche Bank, with analysts lowering their ta

NEW DELHI--(BUSINESS WIRE)--IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and

Eli Lilly's weight-loss and diabetes pill goes on sale in UK pharmacies from Monday, giving patients

Structure Therapeutics (GPCR) maintains a Buy rating, driven by strong Phase 2b data for its oral GL

Eli Lilly's unapproved retatrutide is already popular, as evidenced by the black market for it. This

NVO's U.S. launch of Awiqli introduces the first once-weekly basal insulin, potentially giving the c

BURLINGTON, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Compan

Amylyx Pharmaceuticals (AMLX) shares exploded to the upside on August 18th after the company reporte

Amylyx Pharmaceuticals says its GLP-1 receptor antagonist, avexitide, met both the primary and secon

Global Partners (GLP) could produce exceptional returns because of its solid growth attributes.

Amgen is developing a highly differentiated GLP-1 product. Regeneron has a pair of promising GLP-1 c

Eli Lilly has faced spotty insurance coverage for its GLP-1 medicines in the weight-loss market. How

NVO's GLP-1 pills offer fresh momentum, but Eli Lilly's fast-growing injectable and oral therapies t

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

Final histology and laboratory analyses support the study's safety and performance objectives THE WO

Global Partners (NYSE:GLP) reported quarterly earnings of $1.86 per share which beat the analyst con

Global Partners (NYSE:GLP) reported quarterly earnings of $1.85 per share which beat the analyst con

Stifel analyst Selman Akyol maintains Global Partners (NYSE:GLP) with a Hold and raises the price

Market sentiment declines, Nasdaq falls 1%. Nvidia down 5%, Salesforce up 4% in earnings. Initial jo

U.S. stock futures lower, Carter's and Dell report earnings, Global Partners and Block announce

Stifel analyst Selman Akyol maintains Global Partners (NYSE:GLP) with a Hold and lowers the price

Global Partners (NYSE:GLP) reported quarterly earnings of $0.66 per share which missed the analyst c

Global Partners (NYSE:GLP) reported quarterly earnings of $0.55 per share which missed the analyst c

Global Partners LP (NYSE:GLP) ("Global") today announced that it has priced an upsized priva

Global Partners LP (NYSE:GLP) ("Global") today announced that it intends to commence a priva

Global Partners LP (NYSE:GLP) announces with deep sadness the passing of Richard Slifka, Chairman of

U.S. stocks rallied Thursday after the Trump administration signed its first major trade agreement w

Global Partners (NYSE:GLP) reported quarterly earnings of $0.36 per share which beat the analyst con

Stifel analyst Selman Akyol downgrades Global Partners (NYSE:GLP) from Buy to Hold and raises the

Global Partners (NYSE:GLP) reported quarterly earnings of $0.52 per share which beat the analyst con